MedicineCancer BiologyOncologyCancer GeneticsMolecular OncologyTumor ProgressionBiomarkers In Genitourinary CancerCancer BiomarkersCancer Survival AnalysisKidney CancerMolecular Tumor ProfilingRenal Cell CarcinomaFuhrman GradingLymph Node MetastasesPeroxisome Proliferator-activated Receptor Gamma RegulationPeroxisome Proliferator-activated Receptor SignalingPrognostic Factors AnalysisPrognostic Tumor MarkersPten InactivationTumor Size Prognosis
OBJECTIVE: To explore association of peroxisome proliferator-activated receptor gamma (PPAR-γ) and phosphatase and tensin homolog (PTEN) expressions with prognosis of renal cell carcinoma (RCC). METHODS: Our study subjects included 87 RCC tissues, 28 paracarcinoma tissues and 21 normal renal tissues. PPAR-γ and PTEN detection was conducted using immunohistochemistry staining. The association of PPAR-γ and PTEN with the clinical parameters and prognosis of RCC was analyzed. Kaplan-Meier method and Cox's proportional hazards regression model were used for exploring the relation between variables and prognosis. RESULTS: Among normal renal tissues, para-carcinoma tissues and renal cell carcinomas, positive PPAR-γ expression presented with a progressive tendency (P < 0.001), while positive PTEN expression a degressive tendency (P < 0.001). PPAR-γ expressions were closely related to tumor size, clinical stage and lymph node metastases (all P < 0.05). PTEN expressions were in close association with tumor size, Fuhrman grading, lymph node metastases (all P < 0.05). PPAR-γ expressions were in a negative relation with PTEN expressions (r = -0.417, P < 0.001). Negative PPAR-γ expressions confer a significantly higher overall survival rate than positive PPAR-γ expressions (P = 0.015), while negative PTEN expressions confer a significantly lower overall survival rate than positive PTEN expressions (P = 0.003). Clinical staging, Fuhrman grading, lymph node metastases, PPAR-γ and PTEN were independent prognostic factors for prognosis (all P < 0.05). CONCLUSION: PPAR-γ and PTEN expressions are related to the clinical parameters and prognosis of RCC and may be a biomarker for prognosis of RCC.
24
Sunitinib versus Interferon Alfa in Metastatic Renal-Cell Carcinoma
Robert J. Motzer, Thomas E. Hutson, Piotr Tomczak et al. · New England Journal of Medicine · 2007 · 5.8K citations · Full text
Medicine, Oncology, Pharmacology +14
Daniela Bonofiglio, Sabrina Gabriele, Saveria Aquila et al. · Clinical Cancer Research · 2005 · 153 citations · Full text